+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Advanced Cancer Pain Management(ACPM) - Market Insights, Epidemiology and Market Forecast - 2028

  • ID: 4911963
  • Drug Pipelines
  • January 2020
  • Region: Global
  • 142 pages
  • DelveInsight
1 of 3

FEATURED COMPANIES

  • Pfizer
  • Tetra Bio-Pharma Inc.
  • Wex Pharma
  • MORE
The ‘Advanced Cancer Pain Management (ACPM) - Market Insights, Epidemiology and Market Forecast-2028 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of ACPMs in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Advanced Cancer Pain Management (ACPM) from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan
Study Period: 2017-2028

Advanced Cancer Pain Management (ACPM) - Disease Understanding and Treatment Algorithm

Pain is the commonest symptom of cancer at diagnosis and rises in prevalence throughout and beyond cancer treatment and continues to be a major source of suffering in advanced cancer with adverse effects on patients’ life quality and caregiver distress. This includes different types of pain such as neuropathic, incident or breakthrough, and bone pain associated with poor pain control and with a negative impact on physical, cognitive, and social functioning and mood.

The Advanced Cancer Pain Management (ACPM) market report gives the thorough understanding of the Advanced Cancer Pain Management by including details such as disease definition, classification, symptoms, etiology, pathophysiology and clinical assessment. It also provides treatment algorithms and treatment guidelines for Advanced Cancer Pain Management in the US and Europe.

Advanced Cancer Pain Management Epidemiology

The Advanced Cancer Pain Management (ACPM) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Incident Cases of Advanced Stage Cancers, Incidence of Cancer Pain based on Etiologies, Incidence of Chemotherapy Induced Peripheral Neuropathy, Severity Based Incidence of Cancer Pain, Total Incidence of Cancer Pain based on Pathophysiology, Incidence of Cancer Pain based on Temporal Variations, Incidence of Breakthrough Pain, Incidence of Cancer Pain based on duration) scenario of Advanced Cancer Pain Management (ACPM) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.

According to this research, the total number of Incident cases of Advanced Cancer Pain Management (ACPM) in 7 MM was found to be 1,537,681, in the year 2017.

Advanced Cancer Pain Management Drug Chapters

This segment of the Advanced Cancer Pain Management report encloses the detailed analysis of late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Opioid based treatments are the mainstay of moderate-to-severe cancer-related pain. The goal of long-term opioid treatment is to provide sustained, clinically meaningful relief of pain with side effects that are tolerable and an overall benefit to quality of life.

Advanced Cancer Pain Management Market Outlook

The Advanced Cancer Pain Management market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to this research, the market of Advanced Cancer Pain Management in 7MM was found to be USD 871.50 Million in 2017, and is expected to increase during the course of the study period (2017-2028). Among the 7MM, the United States accounts for the largest market size of Acute Bacterial Prostatitis, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

Advanced Cancer Pain Management Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Advanced Cancer Pain Management Report Insights
  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Key strengths
  • 9 Years Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Key Cross Competition
  • Market Size by Therapies
  • Drugs Uptake

Key assessments
  • Pipeline Product Profiles
  • Key Products and Key Players
  • Market Drivers and Barriers

Key Benefits
  • This report will help to develop Business Strategies by understanding the trends shaping and driving Advanced Cancer Pain Management market
  • Organize sales and marketing efforts by identifying the best opportunities for Advanced Cancer Pain Management market
  • To understand the future market competition in the Advanced Cancer Pain Management market.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Pfizer
  • Tetra Bio-Pharma Inc.
  • Wex Pharma
  • MORE
1. Key Insights

2. Advanced Cancer Pain Management Market Overview at a Glance
2.1. Market Share (%) of Advanced Cancer Pain Management in 2017 – 7MM
2.2. Market Share (%) of Advanced Cancer Pain Management in 2028 – 7MM

3. Disease Background and Overview
3.1. Introduction
3.2. Etiology and types
3.3. Cancer Pain Classification Systems
3.3.1. International Association for the Study of Pain (IASP) Taxonomy
3.3.2. ICD-11
3.3.3. Edmonton Classification System for Cancer Pain (ECS-CP)
3.4. Cancer Pain Pathophysiology
3.5. Cancer Pain Syndromes
3.6. Clinical Presentation and Assessment of Pain

4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Incidence of Cancer Pain based on Etiologies in 7MM
4.3. Assumptions and Rationale: 7MM
4.4. Forecast Parameters

5. Country Wise-Epidemiology
5.1. The United States
5.1.1. Total Incident Cases of Advanced Stage Cancers in the United States
5.1.2. Incidence of Cancer Pain based on Etiologies in the United States
5.1.3. Incidence of Chemotherapy Induced Peripheral Neuropathy (CIPN) in the United States
5.1.4. Severity Based Incidence of Cancer Pain on in the United States
5.1.5. Total Incidence of Cancer Pain based on Pathophysiology in the United States
5.1.6. Incidence of Cancer Pain based on Temporal Variations in the United States
5.1.7. Incidence of Breakthrough Pain in the United States
5.1.8. Incidence of Cancer Pain based on duration in the United States
5.2. EU-5
5.3. Germany
5.3.1. Total Incident Cases of Advanced Stage Cancers in Germany
5.3.2. Incidence of Cancer Pain based on Etiologies in Germany
5.3.3. Incidence of Chemotherapy Induced Peripheral Neuropathy (CIPN) in Germany
5.3.4. Severity Based Incidence of Cancer Pain on in Germany
5.3.5. Total Incidence of Cancer Pain based on Pathophysiology in Germany
5.3.6. Incidence of Cancer Pain based on Temporal Variations in Germany
5.3.7. Incidence of Breakthrough Pain in Germany
5.3.8. Incidence of Cancer Pain based on duration in Germany
5.4. France
5.4.1. Total Incident Cases of Advanced Stage Cancers in France
5.4.2. Incidence of Cancer Pain based on Etiologies in France
5.4.3. Incidence of Chemotherapy Induced Peripheral Neuropathy (CIPN) in France
5.4.4. Severity Based Incidence of Cancer Pain on in France
5.4.5. Total Incidence of Cancer Pain based on Pathophysiology in France
5.4.6. Incidence of Cancer Pain based on Temporal Variations in France
5.4.7. Incidence of Breakthrough Pain in France
5.4.8. Incidence of Cancer Pain based on duration in France
5.5. Italy
5.5.1. Total Incident Cases of Advanced Stage Cancers in Italy
5.5.2. Incidence of Cancer Pain based on Etiologies in Italy
5.5.3. Incidence of Chemotherapy Induced Peripheral Neuropathy (CIPN) in Italy
5.5.4. Severity Based Incidence of Cancer Pain on in Italy
5.5.5. Total Incidence of Cancer Pain based on Pathophysiology in Italy
5.5.6. Incidence of Cancer Pain based on Temporal Variations in Italy
5.5.7. Incidence of Breakthrough Pain in Italy
5.5.8. Incidence of Cancer Pain based on duration in Italy
5.6. Spain
5.6.1. Total Incident Cases of Advanced Stage Cancers in Spain
5.6.2. Incidence of Cancer Pain based on Etiologies in Spain
5.6.3. Incidence of Chemotherapy Induced Peripheral Neuropathy (CIPN) in Spain
5.6.4. Severity Based Incidence of Cancer Pain on in Spain
5.6.5. Total Incidence of Cancer Pain based on Pathophysiology in Spain
5.6.6. Incidence of Cancer Pain based on Temporal Variations in Spain
5.6.7. Incidence of Breakthrough Pain in Spain
5.6.8. Incidence of Cancer Pain based on duration in Spain
5.7. United Kingdom
5.7.1. Total Incident Cases of Advanced Stage Cancers in United Kingdom
5.7.2. Incidence of Cancer Pain based on Etiologies in United Kingdom
5.7.3. Incidence of Chemotherapy Induced Peripheral Neuropathy (CIPN) in United Kingdom
5.7.4. Severity Based Incidence of Cancer Pain on in United Kingdom
5.7.5. Total Incidence of Cancer Pain based on Pathophysiology in United Kingdom
5.7.6. Incidence of Cancer Pain based on Temporal Variations in United Kingdom
5.7.7. Incidence of Breakthrough Pain in United Kingdom
5.7.8. Incidence of Cancer Pain based on duration in United Kingdom
5.8. Japan
5.8.1. Total Incident Cases of Advanced Stage Cancers in Japan
5.8.2. Incidence of Cancer Pain based on Etiologies in Japan
5.8.3. Incidence of Chemotherapy Induced Peripheral Neuropathy (CIPN) in Japan
5.8.4. Severity Based Incidence of Cancer Pain on in Japan
5.8.5. Total Incidence of Cancer Pain based on Pathophysiology in Japan
5.8.6. Incidence of Cancer Pain based on Temporal Variations in Japan
5.8.7. Incidence of Breakthrough Pain in Japan
5.8.8. Incidence of Cancer Pain based on duration in Japan

6. Treatment and Management
6.1. NCCN Guidelines
6.2. ESMO Clinical Practice Guidelines
6.3. Spanish Guidelines
6.4. Multimodal Personalized Management of Cancer Pain
6.5. Patient Journey
6.6. The Role of Cannabinoids In Cancer Pain Management

7. Unmet Needs

8. Case Studies
8.1. Case Studies in Pain Management: Cancer Pain
8.2. Cancer–related visceral pain
8.3. Complex Pain Management: Case study

9. Emerging drugs
9.1. PPP011: Tetra Bio-Pharma Inc.
9.1.1. Product Description
9.1.2. Product Development Activities
9.1.3. Clinical development
9.1.3.1. Clinical Trials Information
9.1.4. Product Profile
9.2. Halneuron: Wex Pharma
9.2.1. Product Description
9.2.2. Product Development Activities
9.2.3. Clinical development
9.2.3.1. Clinical Trials Information
9.2.4. Safety and Efficacy
9.2.5. Product Profile
9.3. Tanezumab: Pfizer
9.3.1. Product Description
9.3.2. Product Development Activities
9.3.3. Clinical development
9.3.3.1. Clinical Trials Information
9.3.4. Product Profile

10. Other Product of interest
10.1. Tetrodotoxin: Wex Pharma
10.1.1. Product Description
10.1.2. Clinical development
10.1.2.1. Clinical Trials Information
10.1.3. Safety and Efficacy
10.1.4. Product Profile
10.2. Sativex: GW Pharmaceuticals
10.2.1. Product Description
10.2.2. Product Development Activities
10.2.3. Clinical development
10.2.3.1. Clinical Trials Information
10.2.4. Safety and Efficacy
10.2.5. Product Profile
10.3. NPC-06: Nobelpharma
10.3.1. Product Description
10.3.2. Product Development Activities
10.3.3. Clinical development
10.3.3.1. Clinical Trials Information
10.3.4. Product Profile

11. Advanced Cancer Pain Management: 7 Major Market Analysis
11.1. Key Findings
11.2. Market Size of Advanced Cancer Pain Management in 7MM
11.3. Market Outlook: 7MM
11.4. Forecast Parameters
11.5. United States Market Size
11.5.1. Total Market size of Advanced Cancer Pain Management
11.5.2. Market Size by Therapies

12. EU-5 Countries: Market Size
12.1. Germany
12.1.1. Total Market size of Advanced Cancer Pain Management in Germany
12.1.2. Market Size by Therapies
12.2. France
12.2.1. Total Market Size of Advanced Cancer Pain Management
12.2.2. Market Size by Therapies
12.3. Italy
12.3.1. Total Market Size of Advanced Cancer Pain Management
12.3.2. Market Size by Therapies
12.4. Spain
12.4.1. Total Market Size of Advanced Cancer Pain Management
12.4.2. Market Size by Therapies
12.5. The United Kingdom
12.5.1. Total Market Size of Advanced Cancer Pain Management
12.5.2. Market Size by Therapies

13. Japan: Market Size
13.1. Japan Market Size
13.1.1. Total Market Size of Advanced Cancer Pain Management
13.1.2. Market Size by Therapies

14. Market Drivers

15. Market Barriers

16. Appendix
16.1. Bibliography
16.2. Report Methodology

17. Researcher Capabilities

18. Disclaimer

19. About the Publisher

List of Tables
Table 1: Acute pain syndromes associated with antineoplastic treatments
Table 2: Chronic pain syndromes associated with cancer treatment
Table 3: Incidence of Cancer Pain based on Etiologies in 7MMin 7MM (2017–2028)
Table 4: Total Incidence of Advanced Stage Cancer in the United States (2017–2028)
Table 5: Incidence of Cancer Pain based on Etiologies in the United States (2017–2028)
Table 6: Incidence of CIPN in the United States (2017–2028)
Table 7: Severity Based Incidence of Cancer Pain in the United States (2017–2028)
Table 8: Pathophysiology Bases Cancer Pain in the United States (2017–2028)
Table 9: Incidence of Cancer Pain based on Temporal Variations in the United States (2017–2028)
Table 10: Incidence Breakthrough Pain in the United States (2017–2028)
Table 11: Incidence of Cancer Pain based on duration in the United States (2017–2028)
Table 12: Total Incidence of Advanced Stage Cancer in Germany (2017–2028)
Table 13: Incidence of Cancer Pain based on Etiologies in Germany (2017–2028)
Table 14: Incidence of CIPN in Germany(2017–2028)
Table 15: Severity Based Incidence of Cancer Pain in Germany (2017–2028)
Table 16: Pathophysiology Bases Cancer Pain Germany (2017–2028)
Table 17: Incidence of Cancer Pain based on Temporal Variations in Germany (2017–2028)
Table 18: Incidence Breakthrough Pain in Germany (2017–2028)
Table 19: Incidence of Cancer Pain based on duration in Germany (2017–2028)
Table 20: Total Incidence of Advanced Stage Cancer in France (2017–2028)
Table 21: Incidence of Cancer Pain based on Etiologies in France (2017–2028)
Table 22: Incidence of CIPN in France (2017–2028)
Table 23: Severity Based Incidence of Cancer Pain in France (2017–2028)
Table 24: Pathophysiology Bases Cancer Pain France (2017–2028)
Table 25: Incidence of Cancer Pain based on Temporal Variations in France (2017–2028)
Table 26: Incidence Breakthrough Pain in France (2017–2028)
Table 27: Incidence of Cancer Pain based on duration in France (2017–2028)
Table 28: Total Incidence of Advanced Stage Cancer in Italy (2017–2028)
Table 29: Incidence of Cancer Pain based on Etiologies in Italy (2017–2028)
Table 30: Incidence of CIPN in Italy(2017–2028)
Table 31: Severity Based Incidence of Cancer Pain in Italy (2017–2028)
Table 32: Pathophysiology Bases Cancer Pain Italy (2017–2028)
Table 33: Incidence of Cancer Pain based on Temporal Variations in Italy (2017–2028)
Table 34: Incidence Breakthrough Pain in Italy (2017–2028)
Table 35: Incidence of Cancer Pain based on duration in Italy (2017–2028)
Table 36: Total Incidence of Advanced Stage Cancer in Spain (2017–2028)
Table 37: Incidence of Cancer Pain based on Etiologies in Spain (2017–2028)
Table 38: Incidence of CIPN in Spain(2017–2028)
Table 39: Severity Based Incidence of Cancer Pain in Spain (2017–2028)
Table 40: Pathophysiology Bases Cancer Pain Spain (2017–2028)
Table 41: Incidence of Cancer Pain based on Temporal Variations in Spain (2017–2028)
Table 42: Incidence Breakthrough Pain in Spain (2017–2028)
Table 43: Incidence of Cancer Pain based on duration in Spain (2017–2028)
Table 44: Total Incidence of Advanced Stage Cancer in United Kingdom (2017–2028)
Table 45: Incidence of Cancer Pain based on Etiologies in United Kingdom (2017–2028)
Table 46: Incidence of CIPN in United Kingdom(2017–2028)
Table 47: Severity Based Incidence of Cancer Pain in United Kingdom (2017–2028)
Table 48: Pathophysiology Bases Cancer Pain United Kingdom (2017–2028)
Table 49: Incidence of Cancer Pain based on Temporal Variations in United Kingdom (2017–2028)
Table 50: Incidence Breakthrough Pain in United Kingdom (2017–2028)
Table 51: Incidence of Cancer Pain based on duration in United Kingdom (2017–2028)
Table 52: Total Incidence of Advanced Stage Cancer in Japan (2017–2028)
Table 53: Incidence of Cancer Pain based on Etiologies in Japan (2017–2028)
Table 54: Incidence of CIPN in Japan(2017–2028)
Table 55: Severity Based Incidence of Cancer Pain in Japan (2017–2028)
Table 56: Pathophysiology Bases Cancer Pain Japan (2017–2028)
Table 57: Incidence of Cancer Pain based on Temporal Variations in Japan (2017–2028)
Table 58: Incidence Breakthrough Pain in Japan (2017–2028)
Table 59: Incidence of Cancer Pain based on duration in Japan (2017–2028)
Table 60: Levels of evidence and grades of recommendation
Table 61: PPP011, Clinical Trial Description, 2020
Table 62: Haleneuron, Clinical Trial Description, 2020
Table 63: Tanezumab, Clinical Trial Description, 2020
Table 64: Tetrodotoxin, Clinical Trial Description, 2020
Table 65: Sativex, Clinical Trial Description, 2020
Table 66: NPC-06, Clinical Trial Description, 2020
Table 67: 7 Major Market Size of Advanced Cancer Pain Management in USD Million (2017-2028)
Table 68: United States Market Size of Advanced Cancer Pain Management in the US, USD Million (2017-2028)
Table 69: Market Size of Advanced Cancer Pain Management by Therapies in the US, in USD Million (2017-2028)
Table 70: Market Size of Advanced Cancer Pain Management in Germany, in USD Million (2017-2028)
Table 71: Market Size of Advanced Cancer Pain Management by Therapies in Germany, in USD Million (2017-2028)
Table 72: Market Size of Advanced Cancer Pain Management in France, in USD Million (2017-2028)
Table 73: Market Size of Advanced Cancer Pain Management by Therapies in France, in USD Million (2017-2028)
Table 74: Market Size of Advanced Cancer Pain Management in Italy, in USD Million (2017-2028)
Table 75: Market Size of Advanced Cancer Pain Management by Therapies in Italy, in USD Million (2017-2028)
Table 76: Market Size of Advanced Cancer Pain Management in Spain, in USD Million (2017-2028)
Table 77: Market Size of Advanced Cancer Pain Management by Therapies in Spain, in USD Million (2017-2028)
Table 78: Market Size of Advanced Cancer Pain Management in the UK, in USD Million (2017-2028)
Table 79: Market Size of Advanced Cancer Pain Management by Therapies in the UK, in USD Million (2017-2028)
Table 80: Market Size of Advanced Cancer Pain Management in Japan, in USD, Million (2017-2028)
Table 81: Market Size of Advanced Cancer Pain Management by Therapies in Japan, in USD Million (2017-2028)

List of Figures
Figure 1: Cancer pain etiologies
Figure 2: Incidence of Cancer Pain based on Etiologies in 7MM (2017–2028)
Figure 3: Total Incidence of Advanced Stage Cancer in the United States (2017–2028)
Figure4: Incidence of Cancer Pain based on Etiologies in the United States (2017–2028)
Figure 5: Incidence of CIPN in the United States (2017–2028)
Figure 6: Severity Based Incidence of Cancer Pain in the United States (2017–2028)
Figure 7: Pathophysiology Bases Cancer Pain in the United States (2017–2028)
Figure8: Incidence of Cancer Pain based on Temporal Variations in the United States (2017–2028)
Figure 9: Incidence Breakthrough Pain in the United States (2017–2028)
Figure 10: Incidence of Cancer Pain based on duration in the United States (2017–2028)
Figure 11: Total Incidence of Advanced Stage Cancer in Germany (2017–2028)
Figure12: Incidence of Cancer Pain based on Etiologies in Germany (2017–2028)
Figure 13: Incidence of CIPN in Germany (2017–2028)
Figure 14: Severity Based Incidence of Cancer Pain in Germany (2017–2028)
Figure 15: Pathophysiology Bases Cancer Pain in Germany (2017–2028)
Figure16: Incidence of Cancer Pain based on Temporal Variations in Germany (2017–2028)
Figure 17: Incidence Breakthrough Pain in Germany (2017–2028)
Figure 18: Incidence of Cancer Pain based on duration in Germany (2017–2028)
Figure 19: Total Incidence of Advanced Stage Cancer in France (2017–2028)
Figure20: Incidence of Cancer Pain based on Etiologies in France (2017–2028)
Figure 21: Incidence of CIPN in France (2017–2028)
Figure 22: Severity Based Incidence of Cancer Pain in France (2017–2028)
Figure 23: Pathophysiology Bases Cancer Pain in France (2017–2028)
Figure24: Incidence of Cancer Pain based on Temporal Variations in France (2017–2028)
Figure 25: Incidence Breakthrough Pain in France (2017–2028)
Figure 26: Incidence of Cancer Pain based on duration in France (2017–2028)
Figure 27: Total Incidence of Advanced Stage Cancer in Italy (2017–2028)
Figure28: Incidence of Cancer Pain based on Etiologies in Italy (2017–2028)
Figure 29: Incidence of CIPN in Italy (2017–2028)
Figure 30: Severity Based Incidence of Cancer Pain in Italy (2017–2028)
Figure 31: Pathophysiology Bases Cancer Pain in Italy (2017–2028)
Figure32: Incidence of Cancer Pain based on Temporal Variations in Italy (2017–2028)
Figure 33: Incidence Breakthrough Pain in Italy (2017–2028)
Figure 34: Incidence of Cancer Pain based on duration in Italy (2017–2028)
Figure 35: Total Incidence of Advanced Stage Cancer in Spain (2017–2028)
Figure36: Incidence of Cancer Pain based on Etiologies in Spain (2017–2028)
Figure 37: Incidence of CIPN in Spain (2017–2028)
Figure 38: Severity Based Incidence of Cancer Pain in Spain (2017–2028)
Figure 39: Pathophysiology Bases Cancer Pain in Spain (2017–2028)
Figure40: Incidence of Cancer Pain based on Temporal Variations in Spain (2017–2028)
Figure 41: Incidence Breakthrough Pain in Spain (2017–2028)
Figure 42: Incidence of Cancer Pain based on duration in Spain (2017–2028)
Figure 43: Total Incidence of Advanced Stage Cancer in United Kingdom (2017–2028)
Figure44: Incidence of Cancer Pain based on Etiologies in United Kingdom (2017–2028)
Figure 45: Incidence of CIPN in United Kingdom (2017–2028)
Figure 46: Severity Based Incidence of Cancer Pain in United Kingdom (2017–2028)
Figure 47: Pathophysiology Bases Cancer Pain in United Kingdom (2017–2028)
Figure48: Incidence of Cancer Pain based on Temporal Variations in United Kingdom (2017–2028)
Figure 49: Incidence Breakthrough Pain in United Kingdom (2017–2028)
Figure 50: Incidence of Cancer Pain based on duration in United Kingdom (2017–2028)
Figure 51: Total Incidence of Advanced Stage Cancer in Japan (2017–2028)
Figure52: Incidence of Cancer Pain based on Etiologies in Japan (2017–2028)
Figure 53: Incidence of CIPN in Japan (2017–2028)
Figure 54: Severity Based Incidence of Cancer Pain in Japan (2017–2028)
Figure 55: Pathophysiology Bases Cancer Pain in Japan (2017–2028)
Figure56: Incidence of Cancer Pain based on Temporal Variations in Japan (2017–2028)
Figure 57: Incidence Breakthrough Pain in Japan (2017–2028)
Figure 58: Incidence of Cancer Pain based on duration in Japan (2017–2028)
Figure 59: Modified World Health Organization Analgesic Ladder
Figure 60: Screening and Assessment for patients with cancer pain
Figure 61: Level of pain intensity for cancer patients
Figure 62: Management of patients in opioid tolerant patients
Figure 63: The analgesic trolley model for pain management
Figure 64: The analgesic trolley model for pain management
Figure 65: Patient Journey for ACPM
Figure 66: Unmet needs for ACPM
Figure 67: 7 Major Market Size of Advanced Cancer Pain Management in USD Million (2017-2028)
Figure 68: Market Size of Advanced Cancer Pain Management in the United States, USD Millions (2017-2028)
Figure 69: Market Size of Advanced Cancer Pain Management by Therapies in the US, in USD Million (2017-2028)
Figure 70: Market Size of Advanced Cancer Pain Management in Germany, USD Million (2017-2028)
Figure 71: Market Size of Advanced Cancer Pain Management by Therapies, in Germany, in USD Million (2017-2028)
Figure 72: Market Size of Advanced Cancer Pain Management in France, USD Million (2017-2028)
Figure 73: Market Size of Advanced Cancer Pain Management by Therapies, in France, in USD Million (2017-2028)
Figure 74: Market Size of Advanced Cancer Pain Management in Italy, USD Million (2017-2028)
Figure 75: Market Size of Advanced Cancer Pain Management by Therapies in Italy, in USD Million (2017-2028)
Figure 76: Market Size of Advanced Cancer Pain Management in Spain, USD Million (2017-2028)
Figure 77: Market Size of Advanced Cancer Pain Management by Therapies in Spain, in USD Million (2017-2028)
Figure 78: Market Size of Advanced Cancer Pain Management in the UK, USD Million (2017-2028)
Figure 79: Market Size of Advanced Cancer Pain Management by Therapies in the UK, in USD Million (2017-2028)
Figure 80: Market Size of Advanced Cancer Pain Management in Japan, USD Million (2017-2028)
Figure 81: Market Size of Advanced Cancer Pain Management by Therapies in Japan, in USD Million (2017-2028)
Figure 82: Market drivers for Advanced Cancer Pain Management
Figure 83: Market Barriers for Advanced Cancer Pain Management

Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Tetra Bio-Pharma Inc.
  • Wex Pharma
  • Pfizer
Note: Product cover images may vary from those shown
Adroll
adroll